Atlas Trials

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Clinical trial NCT02419560 · COMPLETED

Trial details

NCT number
NCT02419560
Sponsor
Craig Portell, MD
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoma, Mantle-CellRecurrent Lymphoma, Mantle-Cell
Start date
2015-04-01
Primary completion
2021-05-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.